Autopsy report · NCT00912509

Cross Linking for Treatment of Corneal Infection

“insufficient efficacy”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 4 years 1 month before it stopped.
• 30 participants enrolled.
• Results were posted on the registry 1 year 2 months after it ended.

Vital statistics

Status

Terminated

Phase

Na

Sponsor

Price Vision Group

Sponsor type

Industry

Conditions

Infectious Keratitis

Interventions

riboflavin; UVX Light

Participants

30

Sites

1

Countries

United States

Trials that died the same way

• A Study of HLX06, a Humanized Monoclonal Antibody Targeting Human Vascular Endothelial Growth Factor Receptor-2 in Patients With Advanced Solid Tumors
  “Lack of efficacy” (91% match in meaning)
• Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) and Safety and Efficacy Evaluation of Pioglitazone in Delaying Its Onset
  “Lack of efficacy of the drug; no safety concern” (75% match in meaning)
• Hydroxyurea in Primary Progressive Multiple Sclerosis
  “No efficacy (interim.analysis)” (74% match in meaning)
• Phase Ib/IIa Trial to Evaluate Oregovomab and Nivolumab in Epithelial Cancer of Ovarian, Tubal or Peritoneal Origin
  “The study had poor efficacy.” (74% match in meaning)
• Study to Evaluate the Clinical Benefit Response in Cancer Patients With Advanced Disease With AMT2003 Versus Placebo
  “Lack of efficacy. Stopped at first interim evaluation point” (72% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.